What is PT141 ?
PT-141 (Bremelanotide) is a centrally acting melanocortin receptor agonist used to enhance sexual desire and arousal in both men and women. Originally developed to treat sexual dysfunction, it is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women and is also commonly used off-label in men with low libido or erectile dysfunction—especially when psychological or central causes are suspected. Unlike traditional ED medications, PT-141 works through the brain rather than blood flow.
How does it work?
- PT-141 stimulates the brain’s arousal centers through the melanocortin system:
- CNS-Based Arousal Enhancement
• PT-141 activates melanocortin receptors (MC3R and MC4R) in the hypothalamus, increasing sexual desire and drive by acting on the central nervous system. - Independent of Blood Flow
• Unlike PDE5 inhibitors (like sildenafil or tadalafil), PT-141 does not depend on nitric oxide pathways or vascular mechanisms—making it effective for both genders and for arousal-related dysfunction. - Rapid, On-Demand Effect
• Administered via subcutaneous injection 45–60 minutes before sexual activity, PT-141 enhances arousal, responsiveness, and sensitivity for several hours.
Side effects and Precautions
- Common Side Effects:
• Nausea (transient)
• Flushing or warmth
• Headache
• Injection site reactions - Less Common / Monitor If Present:
• Elevated blood pressure (temporary)
• Fatigue or yawning
• Dizziness
• Darkening of gums or skin (rare with prolonged use)
How it works
US-licensed professionals
Experienced healthcare providers committed to your well-being.
No insurance needed
Upfront pricing, with no hidden fees.
Ongoing medical support
Ongoing assistance with your specific health condition